Animal models of Parkinson's disease: Vertebrate genetics

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 10, 2012, Pages

  Lee, Yunjong ^a   Dawson, Valina L ^a,b   Dawson, Ted M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; PARKIN; PLATELET DERIVED GROWTH FACTOR B; TAMOXIFEN; LRRK2 PROTEIN, HUMAN; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PTEN INDUCED PUTATIVE KINASE; PTEN-INDUCED PUTATIVE KINASE; SIGNAL PEPTIDE; UBIQUITIN PROTEIN LIGASE;

AGING; ALZHEIMER DISEASE; ANIMAL GENETICS; ARTICLE; CELL DEATH; EXPERIMENTAL ANIMAL; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENETIC DISORDER; HUNTINGTON CHOREA; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PROTEIN AGGREGATION; PROTEOMICS; RETROGRADE NERVE FIBER TRANSPORT; RISK FACTOR; SEROTYPE; TRANSGENIC ANIMAL; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; GENETICS; HAPLORHINI; MOUSE; MOUSE MUTANT; RAT; REVIEW; VIROLOGY;

ANIMALIA; MUS; VERTEBRATA;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; HAPLORHINI; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MODELS, GENETIC; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RATS; UBIQUITIN-PROTEIN LIGASES;

EID: 84886652249     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009324     Document Type: Article

References (76)

1. Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, Ko HS, Sasaki M, Ischiropoulos H, Przedborski S, et al. 2007. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci 104: 14807-14812.
2. + channel subunit, SK3. Science 289: 1942-1946.
3. Brocard J, Warot X, Wendling O, Messaddeq N, Vonesch JL, Chambon P, Metzger D. 1997. Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. Proc Natl Acad Sci 94: 14559-14563.
4. Capecchi MR. 1989. The new mouse genetics: Altering the genome by gene targeting. Trends Genet 5: 70-76.
5. Chaudhuri A, Bowling K, Funderburk C, Lawal H, Inamdar A, Wang Z, O'DonnellJM. 2007. Interaction of genetic and environmental factors in a Drosophilaparkinsonism model. J Neurosci 27: 2457-2467.
6. Chen L, Cagniard B, Mathews T, Jones S, Koh HC, Ding Y, Carvey PM, Ling Z, Kang UJ, Zhuang X. 2005. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280: 21418-21426.
7. Churchyard A, Lees AJ. 1997. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 49: 1570-1576.
8. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. 2006. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162-1166.
9. Cloutier M, Wellstead P. 2010. The control systems structures of energy metabolism. J R Soc Interface 7: 651-665.
10. Dauer W, Przedborski S. 2003. Parkinson's disease: Mechanisms and models. Neuron 39: 889-909.
11. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, TieuK, Schmitz Y, Yuan CA, et al. 2002. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci 99: 14524-14529.
12. Dawson TM, Ko HS, Dawson VL. 2010. Genetic animal models of Parkinson's disease. Neuron 66: 646-661.
13. Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H. 2003. Part II: α-Synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45: 14-44.
14. Fernagut PO, Chesselet MF. 2004. α-Synuclein and transgenic mouse models. Neurobiol Dis 17: 123-130.
15. Forno LS. 1987. The Lewy body in Parkinson's disease. Adv Neurol 45: 35-43.
16. Gao L, Zhang J. 2003. Why are some human disease-associated mutations fixed in mice? Trends Genet 19: 678-681.
17. Gautier CA, Kitada T, Shen J. 2008. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci 105: 11364-11369.
18. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. 2002. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34: 521-533.
19. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J, Korf HW, Deller T, Braak H, Auburger G, et al. 2003. Transgenic mice expressing mutant A53T human α-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 24: 419-429.
20. Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken HH, Becker D, Voos W, Leuner K, Muller WE, Kudin AP, et al. 2009. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PloS ONE 4: e5777.
21. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, MeloniEG, Wu N, Ackerson LC, Klapstein GJ, et al. 2003. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278: 43628-43635.
22. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, et al. 2005. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45: 489-496.
23. Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, et al. 2005. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 42: e65.
24. Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci 89: 5547-5551.
25. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, SchumackerPT, Surmeier DJ. 2010. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468: 696-700.
26. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, et al. 2003. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12: 2277-2291.
27. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, Wakeham A, You-Ten AJ, Kalia SK, Horne P, et al. 2005. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci 102: 5215-5220.
28. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A. 2003. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease. Proc Natl Acad Sci 100: 2884-2889.
29. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci 93: 10933-10938.
30. Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, Martella G, Bonsi P, Zhang C, Pothos EN, Shen J. 2007. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci 104: 11441-11446.
31. Kitada T, Tong Y, Gautier CA, Shen J. 2009. Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem 111: 696-702.
32. Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O, Troncoso J, Johnson B, Saffary R, Goh EL, et al. 2005. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, pp38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25: 7968-7978.
33. Ko HS, Kim SW, Sriram SR, Dawson VL, Dawson TM. 2006. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 281: 16193-16196.
34. Koh DW, Dawson TM, Dawson VL. 2005. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res 52: 5-14.
35. Landel CP, Chen SZ, Evans GA. 1990. Reverse genetics using transgenic mice. Annu Rev Physiol 52: 841-851.
36. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL. 2002. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc Natl Acad Sci 99: 8968-8973.
37. Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, et al. 2010. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16: 998-1000.
38. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, et al. 2009. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12: 826-828.
39. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, DingJ, et al. 2009. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant α-synuclein. Neuron 64: 807-827.
40. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. 2002. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci 99: 10813-10818.
41. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-RosenthalCM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, Dawson TM. 1999. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci 96: 5774-5779.
42. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, LeeMK. 2006. Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26: 41-50.
43. Martin I, Dawson VL, Dawson TM. 2011. Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet 12: 301-325.
44. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, SagaraY, Sisk A, Mucke L. 2000. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 287: 1265-1269.
45. Moeller MJ, Soofi A, Sanden S, Floege J, Kriz W, Holzman LB. 2005. An efficient system for tissue-specific overexpression of transgenes in podocytes in vivo. Am J Physiol Renal Physiol 289: F481-F488.
46. Moore DJ, Dawson VL, Dawson TM. 2003. Genetics of Parkinson's disease: What do mutations in DJ-1 tell us? Ann Neurol 54: 281-282.
47. Moore DJ, West AB, Dawson VL, Dawson TM. 2005. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57-87.
48. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, OdoyS, Fujiwara H, Hasegawa M, et al. 2002. Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies. J Clin Invest 110: 1429-1439.
49. Nieto M, Gil-Bea FJ, Dalfo E, Cuadrado M, Cabodevilla F, Sanchez B, Catena S, Sesma T, Ribe E, Ferrer I, et al. 2006. Increased sensitivity to MPTP in human α-synuclein A30P transgenic mice. Neurobiol Aging 27: 848-856.
50. Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Horsten S, Schmidt T, BoyJ, Kuhn M, Nguyen HP, Teismann P, et al. 2008. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 28: 2471-2484.
51. Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM. 2011. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144: 67-78.
52. Paterna JC, Leng A, Weber E, Feldon J, Bueler H. 2007. DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol Ther 15: 698-704.
53. Perez FA, Curtis WR, Palmiter RD. 2005. Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci 6: 71.
54. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
55. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, et al. 2011. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PloS ONE 6: e18568.
56. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ. 2002. Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp Neurol 175: 35-48.
57. Rockenstein E, Crews L, Masliah E. 2007. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59: 1093-1102.
58. Rosenthal N, Brown S. 2007. The mouse ascending: Perspectives for human-disease models. Nat Cell Biol 9: 993-999.
59. Rulicke T, Montagutelli X, Pintado B, Thon R, Hedrich HJ. 2007. FELASA guidelines for the production and nomenclature of transgenic rodents. Lab Anim 41: 301-311.
60. Savitt JM, Dawson VL, Dawson TM. 2006. Diagnosis and treatment of Parkinson disease: Molecules to medicine. J Clin Invest 116: 1744-1754.
61. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM. 2011. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 144: 689-702.
62. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. 2009. Gene expression profiling of substantia nigra dopamine neurons: Further insights into Parkinson's disease pathology. Brain 132: 1795-1809.
63. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, HulihanM, Peuralinna T, Dutra A, Nussbaum R, et al. 2003. α-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
64. Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E. 2004. Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP. Exp Neurol 186: 158-172.
65. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. α-Synuclein in Lewy bodies. Nature 388: 839-840.
66. Sprengel R, Hasan MT. 2007. Tetracycline-controlled genetic switches. Handb Exp Pharmacol 2007: 49-72.
67. Thomas B, von Coelln R, Mandir AS, Trinkaus DB, Farah MH, Leong Lim K, Calingasan NY, Flint Beal M, Dawson VL, Dawson TM. 2007. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol Dis 26: 312-322.
68. Thomas B, Mandir AS, West N, Liu Y, Andrabi SA, Stirling W, Dawson VL, Dawson TM, Lee MK. 2011. Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation. PloS ONE 6: e16706.
69. Tong Y, Shen J. 2009. α-Synuclein and LRRK2: Partners in crime. Neuron 64: 771-773.
70. Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, Dawson VL, Dawson TM. 2004. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci 101: 10744-10749.
71. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, et al. 2008. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28: 3384-3391.
72. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, AgarwalaR, Ainscough R, Alexandersson M, An P, et al. 2002. Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520-562.
73. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci 102: 16842-16847.
74. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, et al. 2007. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223-232.
75. Wild P, Dikic I. 2010. Mitochondria get a Parkin' ticket. Nat Cell Biol 12: 104-106.
76. Zhou H, Falkenburger BH, Schulz JB, Tieu K, Xu Z, Xia XG. 2007. Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci 3: 242-250.